GE Healthcare’s AIR Recon DL Receives FDA Clearance of 3D & Motion-Insensitive Imaging Applications for Next-Level Image Quality and Patient Experience in MRI

Summation

  • “By expanding AIR Recon DL to 3D and PROPELLER, GE Healthcare has closed the gaps in our ability to provide improved image quality and patient experience to all our patients across exam types, particularly for brain imaging where we rely heavily on 3D sequences and musculoskeletal imaging where PROPELLER is important for reducing image quality variability and eliminating repeat sequences due to motion,” says Dr.
  • Additionally, AIR Recon DL is now compatible with PROPELLER, a motion-insensitive imaging sequence particularly important for anatomies susceptible to motion such as respiration during MRI exams, as well as pediatric, neurodegenerative, geriatric, and claustrophobic patients who have difficulty remaining physically still for the duration of an MRI scan.
  • AIR Recon DL and the recent extensions are available on new GE Healthcare MRI scanners, and as an upgrade for the vast majority of GE Healthcare's installed 1.

GE Healthcare announced US FDA 510(k) clearance of its breakthrough AIR Recon DL for 3D and PROPELLER imaging sequences1. The benefits of AIR Recon DL are extended by these new features to nearly all Magnetic Resonance Imaging (MRI) clinical procedures, covering all anatomies and enabling better image quality, shorter scan times, and enhanced patient experience.

Already, GE Healthcare’s AIR Recon DL deep learning-based image reconstruction technology for MRI has fundamentally shifted the balance between image quality and scan time. Now, with the solution’s expanded compatibility from 2D to 3D imaging sequences, physicians can quickly and confidently diagnose patients with improved signal-to-noise ratio (SNR) and sharpness. 3D imaging provides for more clinical efficiency, allowing radiologists to eliminate the need for multiple 2D acquisitions – potentially leading to faster diagnosis.

Additionally, AIR Recon DL is now compatible with PROPELLER, a motion-insensitive imaging sequence particularly important for anatomies susceptible to motion such as respiration during MRI exams, as well as pediatric, neurodegenerative, geriatric, and claustrophobic patients who have difficulty remaining physically still for the duration of an MRI scan. As a result, physicians can get sharper images without the need for repeat scans – translating to faster patient throughput, improved scheduling, shorter exam time, and faster diagnosis, helping to create an all-round better patient experience.

As of September 2022, at least 3.5 million patients globally have been scanned with AIR Recon DL. According to a recent AIR Recon DL 3D and PROPELLER reader study:

  • 100% of the participants said that the deep learning solution provides better signal-to-noise ratio and better or equivalent image sharpness than conventional image reconstruction;
  • 99% also said AIR Recon DL provides better or equivalent lesion conspicuity; and
  • Reports also indicate up to 50% reduction in exam times, creating efficiency in workflow and increased productivity2.

“By expanding AIR Recon DL to 3D and PROPELLER, GE Healthcare has closed the gaps in our ability to provide improved image quality and patient experience to all our patients across exam types, particularly for brain imaging where we rely heavily on 3D sequences and musculoskeletal imaging where PROPELLER is important for reducing image quality variability and eliminating repeat sequences due to motion,” says Dr. Tiron Pechet, Radiologist and Assistant Medical Director at Shields Health Care Group.

AIR Recon DL and the recent extensions are available on new GE Healthcare MRI scanners, and as an upgrade for the vast majority of GE Healthcare’s installed 1.5T and 3.0T MRI systems. Beyond its efficiency and productivity benefits to the industry, this upgrade will enable previously installed scanners to refresh and function like new systems – allowing imaging facilities to enjoy the most advanced imaging capabilities on their existing systems, while saving on capital expenditure amid today’s cost constrained environment.

More News

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

"We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company.  We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer."

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

By using this website you agree to accept Medical Device News Magazine Privacy Policy